Form 4: Vaxcyte Director Teri Loxam Executes Stock Option and Sells Shares Under 10b5-1 Plan

Director Teri Loxam exercised stock options and sold Vaxcyte shares under a pre-arranged Rule 10b5-1 trading plan.

Summary

• Teri Loxam, a director of Vaxcyte, Inc., executed a transaction involving the company's stock on September 17, 2024.
• Loxam exercised stock options to acquire 6,250 shares of common stock at a price of $22.70 per share.
• Concurrently, Loxam sold a total of 6,250 shares of common stock at weighted average prices ranging from $114.6372 to $117.51 per share.
• These sales were conducted under a pre-arranged Rule 10b5-1 trading plan adopted on June 18, 2024.
• Following these transactions, Loxam directly owns 7,175 shares of Vaxcyte common stock and 12,500 derivative securities (stock options).

Sentiment

Score: 5

Explanation: Neutral sentiment as the transactions are part of a pre-planned trading strategy and do not necessarily indicate a change in the director's confidence in the company.

Positives

• The transactions were executed under a pre-arranged 10b5-1 trading plan, which can provide transparency and reduce concerns about insider trading.

Risks

• Sales of shares by a director could be perceived negatively by the market, although the 10b5-1 plan mitigates this concern.

Industry Context

Insider transactions are common, and the use of a 10b5-1 plan is a standard practice to avoid accusations of trading on non-public information. The market will likely assess the impact based on the overall volume and context of the transactions.

Comparison to Industry Standards

• Directors and officers commonly use 10b5-1 trading plans to manage their stock holdings in publicly traded companies.
• The volume of shares sold is relatively small compared to the overall market capitalization of Vaxcyte, suggesting a limited impact.
• Comparable companies often see similar insider transactions, and the market typically focuses on the reasons behind the transactions and the overall financial health of the company.

Stakeholder Impact

• The transactions could have a minor impact on shareholders due to the sale of shares, but the 10b5-1 plan mitigates concerns.
• Employees may be indirectly affected by market perceptions of insider transactions.

Key Dates